Data altered in Japanese research for Novartis blood pressure drug

Data altered in Japanese research for Novartis blood pressure drug

TOKYO, Japan - Toshikazu Yoshikawa (2nd from L), president of the Kyoto Prefectural University of Medicine, and Shinji Fushiki (L), the university窶冱 vice president, bow toward the end of a press conference in Kyoto on July 11, 2013. Yoshikawa apologized as the university found that data employed in a clinical study on Novartis Pharama K.K.'s blockbuster blood pressure lowering drug Diovan were manipulated.

  • Product Code
  • ILEA001184749
  • Registered date
  • 2013/7/11 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2013 Kyodo News
  • Media size
  • 3968 × 2417 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 758.79(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Research to start on blood tests to detect 13 cancer types

    Research to start on blood tests to detect 13 cancer types

    TOKYO, Japan - Researchers announce the commencement of a project to develop ways of detecting 13 types of cancer from a single blood sample at a press conference in Tokyo on Aug. 18, 2014. Making the announcement were Kenji Kurata (L), president of the New Energy and Industrial Technology Development Organization, Tomomitsu Hotta (C), president of the National Cancer Center, and Tetsu Yonehara, head of Toray Industries Inc.'s New Frontiers Research Laboratories.
      Novartis management replaced

      Novartis management replaced

      TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.
        Novartis management replaced

        Novartis management replaced

        TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
          Novartis management replaced

          Novartis management replaced

          TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
            Takeda chief apologizes over data misuse in drug ad

            Takeda chief apologizes over data misuse in drug ad

            TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
              Takeda chief apologizes over data misuse in drug ad

              Takeda chief apologizes over data misuse in drug ad

              TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
                Novartis scandal

                Novartis scandal

                TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                  Novartis scandal

                  Novartis scandal

                  TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                    Novartis division head Epstein

                    Novartis division head Epstein

                    TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                      Success of new treatment for pancreatitis

                      Success of new treatment for pancreatitis

                      OSAKA, Japan - Toshinori Ito, professor at Osaka University, Graduate School of Medicine, holds a press conference in Suita, Osaka Prefecture, on Aug. 21, 2013. Doctors at Osaka University Hospital in July successfully removed a chronically inflamed pancreas from a pancreatitis patient before separating the organ's insulin-producing islets and transplanting them back into the patient, marking a new form of treatment, Ito said.